Gastrointestinal adverse events · residents of long‐term care (≥ 65 years) with pressure ulcers; inpatients with pressure ulcers
It is very uncertain whether summary of findings table ‐ Protein, arginine, zinc and antioxidants changes side effects: at least one adverse gastrointestinal event compared with standard diet or placebo (very low certainty).
1 finding from 1 review
Gastrointestinal adverse events · malnourished patients with pressure ulcers
It is very uncertain whether summary of findings table ‐ Arginine and micronutrients changes side effects: at least one adverse gastrointestinal event compared with standard diet (very low certainty).
1 finding from 1 review
Adverse effects (number of participants who had the event) · People with American cutaneous and mucocutaneous leishmaniasis
Oral miltefosine (1.2 to 3.3 mg/kg/d 28 days) probably leads to higher adverse effects (number of participants who had the event) compared with meglumine antimoniate (20 mg/kg 20 days) (moderate certainty).
1 finding from 1 review
Proportion of participants with infectious adverse effects · participants with hidradenitis suppurativa
Adalimumab every other week showed no clear difference in proportion of participants with infectious adverse effects compared with placebo (high certainty).
1 finding from 1 review
Proportion of participants with infectious adverse effects · participants with hidradenitis suppurativa
Adalimumab weekly showed no clear difference in proportion of participants with infectious adverse effects compared with placebo (moderate certainty).
1 finding from 1 review
Adverse effects ‐ complication rate at 1 week after surgery · participants with hidradenitis suppurativa
Gentamicin sponge showed no clear difference in adverse effects ‐ complication rate at 1 week after surgery compared with primary closure alone (moderate certainty).
1 finding from 1 review
Adverse effects during use of the preventative intervention · participants with recurrent herpes labialis
Valaciclovir (short‐term) showed no clear difference in adverse effects during use of the preventative intervention compared with placebo (moderate certainty).
1 finding from 1 review
Adverse effects during use of the preventative intervention · participants with recurrent herpes labialis
Valaciclovir (long‐term) showed no clear difference in adverse effects during use of the preventative intervention compared with placebo (moderate certainty).
1 finding from 1 review
Adverse effects during use of the preventative intervention · participants with recurrent herpes labialis
It is very uncertain whether valaciclovir (suppressive regimen changes adverse effects during use of the preventative intervention compared with episodic regimen) (very low certainty).
1 finding from 1 review
Adverse effects during use of the preventative intervention · participants with recurrent herpes labialis
Topical aciclovir (short‐term) showed no clear difference in adverse effects during use of the preventative intervention compared with placebo (low certainty).
1 finding from 1 review
Adverse effects during use of the preventative intervention · participants with recurrent herpes labialis
1 finding from 1 review
Adverse effects during use of the preventative intervention · participants with recurrent herpes labialis
Thymopentin showed no clear difference in adverse effects during use of the preventative intervention compared with placebo (moderate certainty).
1 finding from 1 review
Adverse effects during use of the preventative intervention · participants with recurrent herpes labialis
HSV vaccination showed no clear difference in adverse effects during use of the preventative intervention compared with placebo (moderate certainty).
1 finding from 1 review
Adverse effects during use of the preventative intervention · participants with recurrent herpes labialis
Yellow fever vaccination showed no clear difference in adverse effects during use of the preventative intervention compared with placebo (moderate certainty).
1 finding from 1 review
Number of participants reporting non‐serious adverse effects · participants with hidradenitis suppurativa
Ethinyloestradiol and cyproterone acetate probably leads to lower number of participants reporting non‐serious adverse effects compared with ethinyloestradiol and norgestrel (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · workers at risk of occupational irritant hand dermatitis
1 finding from 1 review
Withdrawals due to adverse events · workers at risk of occupational irritant hand dermatitis
1 finding from 1 review
Withdrawals due to adverse events · workers at risk of occupational irritant hand dermatitis
1 finding from 1 review
Withdrawals due to adverse events · workers at risk of occupational irritant hand dermatitis
1 finding from 1 review
Adverse effects ‐ complication rate at 3 months after surgery · participants with hidradenitis suppurativa
Gentamicin sponge showed no clear difference in adverse effects ‐ complication rate at 3 months after surgery compared with primary closure alone (moderate certainty).
1 finding from 1 review